Sacubitril/Valsartan for Heart Failure with Preserved Ejection Fraction: A Cost-Effectiveness Analysis from the Perspective of the Chinese Healthcare System

[1]  Yake Lou,et al.  Cost-Effectiveness of Adding Empagliflozin to Standard Treatment for Heart Failure with Preserved Ejection Fraction Patients in China , 2022, American Journal of Cardiovascular Drugs.

[2]  D. Stub,et al.  Cost-Effectiveness of Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction , 2022, Circulation. Cardiovascular quality and outcomes.

[3]  Xinyue Dong,et al.  Cost Effectiveness of the First‐in‐Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting , 2022, PharmacoEconomics.

[4]  Jun Xie,et al.  Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China , 2022, Frontiers in Cardiovascular Medicine.

[5]  Akshay S. Desai,et al.  Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. , 2022, The New England journal of medicine.

[6]  A. Cai,et al.  Clinical characteristics and 1‐year outcomes in hospitalized patients with heart failure with preserved ejection fraction: results from the China Cardiovascular Association Database‐Heart Failure Center Registry , 2022, European journal of heart failure.

[7]  Yake Lou,et al.  Sacubitril-valsartan for the treatment of hypertension in China: A cost-utility analysis based on meta-analysis of randomized controlled trials , 2022, Frontiers in Public Health.

[8]  Report on Cardiovascular Health and Diseases in China 2021: An Updated Summary. , 2022, Biomedical and environmental sciences : BES.

[9]  R. Krittayaphong,et al.  Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction , 2022, American Journal of Cardiovascular Drugs.

[10]  Jin Liu,et al.  Five‐year mortality of heart failure with preserved, mildly reduced, and reduced ejection fraction in a 4880 Chinese cohort , 2022, ESC heart failure.

[11]  M. Drummond,et al.  Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations , 2022, BMC Medicine.

[12]  S. Staniszewska,et al.  Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations , 2022, PharmacoEconomics.

[13]  G. Sinagra,et al.  [ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: what's new?] , 2022, Giornale italiano di cardiologia.

[14]  C. Strong,et al.  Cost-Effectiveness Evaluation of Add-on Empagliflozin in Patients With Heart Failure and a Reduced Ejection Fraction From the Healthcare System's Perspective in the Asia-Pacific Region , 2021, Frontiers in Cardiovascular Medicine.

[15]  C. Strong,et al.  Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia–Pacific region , 2021, Cardiovascular Diabetology.

[16]  R. Krittayaphong,et al.  Cost-Utility Analysis of Sacubitril-Valsartan Compared with Enalapril Treatment in Patients with Acute Decompensated Heart Failure in Thailand , 2021, Clinical Drug Investigation.

[17]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.

[18]  P. Ponikowski,et al.  Empagliflozin in Heart Failure with a Preserved Ejection Fraction. , 2021, The New England journal of medicine.

[19]  Xiaodong Lin,et al.  Cost-effectiveness of empagliflozin as a treatment for heart failure with reduced ejection fraction: an analysis from the Chinese healthcare perspective , 2021, Journal of Thoracic Disease.

[20]  M. Metra,et al.  Heart failure in the last year: progress and perspective , 2020, ESC heart failure.

[21]  Jian Zhang,et al.  Cost‐effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China , 2020, ESC heart failure.

[22]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.

[23]  G. Filippatos,et al.  SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials , 2020, The Lancet.

[24]  S. Solomon,et al.  Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction. , 2020, JAMA cardiology.

[25]  Benhong Zhou,et al.  Sacubitril-Valsartan Compared With Enalapril for the Treatment of Heart Failure: A Decision-Analytic Markov Model Simulation in China , 2020, Frontiers in Pharmacology.

[26]  F. Rutten,et al.  Epidemiology of heart failure , 2020, European journal of heart failure.

[27]  M. Metra,et al.  Corrigendum to ‘Prevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey, 2012–2015’ [Eur J Heart Fail 2019;21:1329–1337] , 2020, European journal of heart failure.

[28]  Zengwu Wang,et al.  Prevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey, 2012–2015 , 2019, European journal of heart failure.

[29]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[30]  Akshay S. Desai,et al.  Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. , 2019, The New England journal of medicine.

[31]  Samprit Banerjee,et al.  Prevalence and determinants of Hyperpolypharmacy in adults with heart failure: an observational study from the National Health and Nutrition Examination Survey (NHANES) , 2019, BMC Cardiovascular Disorders.

[32]  G. Fonarow,et al.  Contemporary Epidemiology, Management, and Outcomes of Patients Hospitalized for Heart Failure in China: Results From the China Heart Failure (China-HF) Registry. , 2017, Journal of cardiac failure.

[33]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[34]  M. Herdman,et al.  A comparison of the scaling properties of the English, Spanish, French, and Chinese EQ-5D descriptive systems , 2013, Quality of Life Research.

[35]  S. Silver,et al.  Heart Failure , 1937, The New England journal of medicine.